MONTREAL, Nov. 14, 2017 /CNW Telbec/ - LGC Capital
Ltd. (TSXV: LG) ("LGC") is pleased to announce its strategic
partner Creso Pharma (CPH-ASX) disseminated the following news
release yesterday about the launch of its cannabis-based product
anibidiol® in Switzerland and
Lichtenstein. Of note, Creso Pharma and LGC have agreed that LGC
will be spearheading the distribution of this product in
Southern Africa and Canada through LGC's investee businesses,
subject to their obtaining all necessary regulatory approvals.
Creso Pharma and Virbac launch anibidiol® -
the first Swiss approved hemp product with CBD as a complementary
feed for companion animals
Creso Pharma and Virbac are pleased to announce the launch in
Switzerland of anibidiol®, a
natural complementary feed for companion animals containing a
standardized amount of hemp extract with cannabidiol (CBD), the
non-psychoactive substance of the hemp plant. The product supports
companion animals' immune system, its natural defenses and
contributes to balanced behavior. It is now available for the first
time to Swiss veterinarians.
anibidiol® is the first Swiss Agroscope conformed
complementary feed for companion animals that contains natural hemp
extract with CBD and is THC-free.
anibidiol® promotes the well-being of the animal by
supporting its immunity and natural defense system. anibidiol® also
supports a balanced behavior of the pet.
anibidiol® contains natural full plant hemp extract as
well as hemp seed oil. This proprietary combination of CBD, the
fatty acids Omega 3, Omega 6 and Omega 9, terpenes, flavonoids, and
other active herbal ingredients have a complex interaction which
enhances their overall health-promoting effect. The
anibidiol® product range directly addresses the need for
natural, non-pharmaceutical therapeutic approaches which are well
tolerated by animals. The CBD contained in anibidiol® does
not cause GI and dependency side effects and has a very good safety
and tolerability profile.
In order to guarantee professional advice
anibidiol® is marketed in Switzerland exclusively by Virbac and only
through veterinary practices. The individually-packed portions
contain a granulate formulation, which is mixed once a day with the
pet's food.
anibidiol® was developed by Creso Pharma, an
Australian-Swiss company based in Zug and Perth. It is produced in Switzerland by Creso's partner Swiss-based
food and pharma development company, Domaco, Dr. med Aufdermaur AG
(Domaco) and is marketed exclusively in Switzerland by Virbac (Switzerland) AG, Glattbrugg ZH.
Virbac is a global pharmaceutical animal health company with a
presence in over 100 countries and more than 4,800 employees and
sales subsidiaries in 31 countries. With a turnover of €872 million
in 2016, Virbac ranks today as the 7th largest pharmaceutical
veterinary company worldwide. Virbac operates through presence in
North America (17%), Europe (39%), Latin
America (16%), Far East (15%), and Rest of the World (13%).
Its wide range of vaccines and medicines are used in the prevention
and treatment of the main pathologies for companion and
food-producing animals.
Creso Pharma CEO and Co-Founder Dr. Miri Halperin Wernli said: "We are very excited to
launch anibidiol® in Switzerland
and thrilled to be working in partnership with Virbac, such a
well-established global company in the animal health field. This is
the first introduction of our hemp-based complementary feed
products for companion animals in the veterinary market. "It
is a particularly significant launch for us as it is Creso's first
product launch in Europe and we
intend to follow it with many more. "We look forward to working
with Virbac to successfully promote, market and launch further
quality hemp-based animal health products." The recession-resistant
worldwide animal health market is estimated to be USD 30 billion1 and is projected to
continue to show rapid growth. Forty-one per cent of pet owners
have considered or tried various alternative therapies including
nutritional supplements (29%) and herbal remedies
(7%).2
Creso Pharma Switzerland is a subsidiary of Creso Pharma
Limited, based in Perth,
Australia, and listed on the Australian stock exchange ASX.
Creso Pharma Switzerland develops, produces and markets worldwide
hemp-based innovative nutraceutical products for humans and
complementary feed products for animals. In Switzerland, Creso Pharma Switzerland markets
its products for animal health with Virbac (Switzerland) AG.
www.anibidiol.com
Virbac (Switzerland) Ltd.,
headquartered in Zurich-Glattbrugg, is part of the Virbac Group
from France, which is dedicated
exclusively to animal health, in more than 100 countries and on all
five continents. Virbac (Schweiz) AG has a wide range of innovative
health products for the prophylaxis and treatment of the most
important diseases of domestic animals and livestock.
1 Vetnosis review 2016
2 Brown, L. P. (2001) Pet nutraceuticals: hype or
wave of the future? Nutraceuticals World. January/February 2001 issue, pp. 34–41. Retrieved
31st July 2017 from:
http://www.nutraceuticalsworld.com/issues/2001‐01/view_features/petnutraceuticals/
About Creso Pharma
Creso Pharma brings pharmaceutical expertise and methodological
rigour to the world of medicinal cannabis and strives for the
highest quality in its products. It is the leader in medicinal
cannabis and cannabidiol (CBD) innovation and develops cannabis-
and hemp-derived therapeutic-grade nutraceuticals and medicinal
cannabis products with wide patient and consumer reach for human
and animal health. Creso uses GMP development and manufacturing
standards for its products as a reference of quality excellence
with initial product registrations in Switzerland. It has worldwide rights for a
number of unique and proprietary innovative delivery technologies
which enhance the bioavailability and absorption of
cannabinoids.
About Domaco, Dr. med Aufdermaur AG
Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma
development company that owns the rights to a number of innovative
delivery systems used to administer active ingredients through
galenic forms which is a way of preparing and compounding medicines
in order to optimise their absorption.
About LGC Capital Ltd.:
www.lgc-capital.com
LGC Capital Ltd. is a Canadian incorporated public company
listed on the TSX Venture Exchange (TSXV: LG). LGC's is a
diversified investment company with core holdings in businesses
that provide shareholders with exposure to a diverse range of high
growth businesses, products and services. To date, LGC has entered
into agreements for investments in private cannabis operations
in South Africa, Australia and Canada. The
company also has a strategic alliances with AfriAg (Pty) Ltd. to
grow and distribute medical and recreational cannabis products in
the southern African region for export to regulated and certified
end users around the world; and with Creso Pharma Limited for the
creation of a vertically-integrated cannabis operation, which
includes cultivation, IP generation, product development, and
commercialization. LGC Capital Ltd. is headquartered in
Montreal, Canada.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with
respect to LGC Capital Ltd. ("LGC") and Creso Pharma Limited
("Creso") and their respective operations, strategy, investments,
financial performance and condition. These statements generally can
be identified by use of forward-looking words such as "may",
"will", "expect", "estimate", "anticipate", "intends", "believe" or
"continue" or the negative thereof or similar variations. The
actual results and performance of LGC and Creso, including their
proposed strategic alliance described herein, could differ
materially from those expressed or implied by such statements. Such
statements are qualified in their entirety by the inherent risks
and uncertainties surrounding future expectations. Some important
factors that could cause actual results to differ materially from
expectations include, among other things, general economic and
market factors, competition, government regulation and the factors
described under "Risk Factors and Risk Management" in LGC's
Management's Discussion and Analysis for the fiscal year ended
September 30, 2016, as filed on SEDAR
(www.sedar.com). The cautionary statements qualify all
forward-looking statements attributable to LGC or Creso, as the
case may be, and persons acting on their behalf, respectively.
Unless otherwise stated, all forward-looking statements speak only
as of the date of this press release and neither LGC nor Creso has
any obligation to update such statements, except to the extent
required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE LGC Capital Ltd